AMGEN WINS EPO PATENT FIGHT IN FEDERAL APPEALS COURT; GENETICS INSTITUTE BARRED FROM U.S. MARKET BECAUSE ITS PROCESS DID NOT PRODUCE CLAIMED MATERIAL

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".